2024-11-22 05:00:00
France has more than 8 million people suffering from obesity. In this context, the arrival on the market of anti-obesity treatments Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) represents new hope for patients. Because until now, if you had difficulty losing weight, your options were very limited. These medications are praised by some obesity specialists for their effectiveness. Other health professionals remain cautious and emphasize the lack of perspective on their long-term effects.
In this video, we return to the active ingredient of these new drugs, which imitate a digestive hormone naturally produced by the human body: glucagon-like peptide-1 (GLP-1). This hormone, discovered in the 1980s, acts in particular on insulin secretion and the feeling of satiety.
We also explain the conditions to be eligible for this type of treatment in France, which can only be prescribed by doctors specializing in endocrinology, diabetology or nutrition. Wegogy and Mounjaro are designed to be used as second-line treatment, after failure of nutritional treatment.
To find out more about these new treatments and the excitement they are causing in the financial markets, you will find a complete breakdown below.
Read later
“Understand in three minutes”
The explanatory videos that make up the “Understand in three minutes” series are produced by the Vertical Videos department of the Monde. Broadcast primarily on platforms such as TikTok, Snapchat, Instagram and Facebook, they aim to put major events into context in a short format and make the news accessible to everyone.
The contributions area is reserved for subscribers.
Subscribe to access this discussion space and contribute to the discussion.
Contribute
Reuse this content
1732266450
#antiobesity #drugs #Wegogy #Mounjaro #work #Understand #minutes
What role do Wegovy and Mounjaro play in the treatment of obesity compared to traditional weight loss methods?
**Interview with Dr. Claire Fontaine, Obesity Specialist**
**Interviewer:** Thank you for joining us today, Dr. Fontaine. With over 8 million people in France suffering from obesity, the introduction of Wegovy and Mounjaro signals a significant shift in the treatment landscape. What do you think these medications offer that previous weight loss options did not?
**Dr. Fontaine:** Thank you for having me. These medications are groundbreaking because they target weight loss more effectively by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which plays a role in appetite regulation and glucose metabolism. Unlike traditional weight loss strategies that often rely purely on diet and exercise, Wegovy and Mounjaro can actually help patients reduce their appetite and improve weight loss outcomes, making them a powerful adjunct to lifestyle changes.
**Interviewer:** That’s an interesting point. While many specialists are praising these drugs for their effectiveness, some health professionals remain cautious. Could you elaborate on the potential long-term effects and concerns surrounding these treatments?
**Dr. Fontaine:** Yes, the excitement is tempered by legitimate concerns regarding long-term safety and efficacy. These medications were only recently approved, and we don’t yet have comprehensive data on the prolonged use of these drugs. Potential side effects, the risk of developing other health conditions, and how they might interact with existing health issues are areas that require further research. It’s crucial for patients to have ongoing discussions with their healthcare providers to monitor their health throughout treatment.
**Interviewer:** Given the current obesity epidemic in France, do you believe the benefits of these medications outweigh the risks?
**Dr. Fontaine:** In many cases, yes. For patients who have tried multiple weight loss methods without success, these medications can provide a much-needed tool in their weight loss journey. However, it’s essential to emphasize that they should not replace healthy lifestyle changes. The best results often come from a combination of medication support and behavioral changes.
**Interviewer:** Thank you, Dr. Fontaine. As we continue to witness advancements in obesity treatments, your insights are invaluable for those considering these new options. We look forward to seeing how these treatments develop and their impact on patients moving forward.
**Dr. Fontaine:** Thank you! It’s been a pleasure discussing this important topic.
